EP300 and CBP (KAT3A/3B) are two highly homologous, multidomain, epigenetic coregulators that play central roles in transcription through the acetylation of lysine residues on histones and other proteins. Both enzymes have been implicated in human diseases, especially cancer. From a high‐throughput screen of 191 000 compounds searching for EP300/CBP histone acetyltransferase (HAT) inhibitors, 18 compounds were characterized by a suite of biochemical enzymatic assays and biophysical methods, including X‐ray crystallography and native mass spectrometry. This work resulted in the discovery of three distinct mechanistic classes of EP300/CBP HAT inhibitors, including two classes not previously described. The profiles of an example of each class of inhibitor are described in detail. A subsequent medicinal chemistry effort led to the development of a novel class of orally bioavailable AcCoA‐competitive EP300/CBP HAT inhibitors with in vivo activity. We believe that this work will prove to be a useful guide for other groups interested in the development of HAT inhibitors.

中文翻译：

---

早期发现EP300 / CBP组蛋白乙酰转移酶（HAT）抑制剂的药物发现。

EP300和CBP（KAT3A / 3B）是两种高度同源的多域表观遗传调节剂，它们通过组蛋白和其他蛋白质上赖氨酸残基的乙酰化作用在转录中发挥核心作用。两种酶都与人类疾病特别是癌症有关。在高通量筛选中寻找EP300 / CBP组蛋白乙酰转移酶（HAT）抑制剂的191 000种化合物中，通过一系列生化酶测定法和生物物理方法（包括X射线晶体学和天然质谱）对18种化合物进行了表征。这项工作导致发现了三类不同的EP300 / CBP HAT抑制剂机理，包括先前未描述的两类。详细描述每种抑制剂的实例的概况。随后的药物化学工作导致了具有口服活性的新型一类口服生物可利用的AcCoA竞争性EP300 / CBP HAT抑制剂的开发。我们相信，这项工作将对其他对HAT抑制剂感兴趣的研究小组提供有用的指导。